Getting a therapy to where it needs to work

# Getting a therapy to where it needs to work OCTOBER 12, 2026 Genentech, part of Roche, has agreed to pay $100 million upfront for exclusive worldwide rights to Alector's AL050, a Parkinson's therapy built to get an enzyme into the brain, according to Longevity.Technology, in a report dated October 9, 2026. For a brain-directed therapy, delivery is part of the biological challenge. The AL050 agreement places commercial weight behind an attempt to bring an enzyme across that difficult boundary. AL050 is an enzyme replacement therapy for deficiency of glucosylceramidase, known as GCase. It pairs an engineered GCase enzyme with Alector's Brain Carrier technology, which is designed to cross the blood-brain barrier, according to the report. The deal could be worth much more. Longevity.Technology reports up to $1.17 billion in development, regulatory and sales milestones, plus tiered royalties. Genentech gets the rights to develop, manufacture and sell AL050. The first target is Parkinson's patients with GBA1 mutations. The report says the drug may later be used more broadly. Alector keeps ownership of its Alector Brain Carrier platform, according to the report. That means it can continue to use the delivery technology across the rest of its pipeline. Only AL050 moves to Genentech. Roche's Boris L. Zaïtra is quoted as saying: "By partnering with companies such as Alector, we aim to delay or halt the progression of Parkinson's." The notes do not give clinical data, trial stage or timelines, so the size of the upfront payment against the milestone total is the main signal available. A large share of the value depends on future results and sales. Whether AL050 earns those milestones will rest on clinical evidence that has not been reported here. This is the weakest point of the story: a deal price says something about company confidence, not about whether the drug works. AL050 is an investigational treatment, and readers should not start or stop any medication or treatment without talking to their clinician. Watch for the first details on trial design and timing from Genentech and Alector. The milestones ahead will show whether the delivery strategy can support a useful treatment. That connection between access and effect is where the scientific value lies. Source: Longevity.Technology ---